RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 First Clinical Evidence Offered That Inhibiting P-Selectin May Limit Myocardial Damage during PCI
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 2
SP 19
OP 20
DO 10.1177/155989771302011
UL http://mdc.sagepub.com/content/13/2/19.2.abstract
AB A single dose of inclacumab, a fully human recombinant monoclonal antibody directed against P-selectin, appears to reduce myocardial damage in patients undergoing percutaneous coronary intervention (PCI) as measured by biomarker concentration. Results from a randomized Phase 2 trial showed a reduction in levels of troponin I at 16 and 24 hours post PCI with a single dose of incalcumab 20 mg/kg when administered prior to PCI. The effect of a single dose of inclacumab on myocardial damage was examined in the Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention [SELECT-ACS; Tardif JC et al. J Am Coll Cardiol 2013].